Abstract 2053P
Background
In recent decades, the home care initiative has expanded in the health system, mainly linked to hospitals. The mismatch between available financial resources and advances related to cancer therapy requires projects to improve cost minimization processes.
Methods
The variables collected for each sector were described through monthly totals and averages per year. To verify the existence of an association between expenses with material, medication and chemotherapy and the cost avoided with monthly dehospitalization, Pearson's correlation coefficients and their respective p-values were calculated. Spending on medication and total spending on material, medication and chemotherapy were related to the amount avoided using linear regression models, in order to estimate the effect of increased spending on medication on avoided costs. The same procedure was performed to estimate the effect of increased costs on bed turnover, using linear regressions, and on the number of days of hospitalization avoided per month, using Poisson regression.
Results
Pearson's coefficients confirm a relationship, with a positive sign, between expenses and avoided costs with early dehospitalization, showing a perfect positive relationship between the variables, with a statistically significant p-value. Effect of expenses on total costs with hospitalization avoided on General Hospitalization, Coefficients - Amount spent on medication:100.36; 95% CI (14.26, 186.45); p-value= 0.02. By the linear model, the total avoided cost with discharges was $795,204.52 in the three-year period from 2020 to 2022, for a total of 3,722 avoided hospitalization days and an average cost avoided with discharges of $70,146.06. Effect of expenses on the days of hospitalization avoided (Poisson regression) was statistically significant in all variables (p-value<0.001).
Conclusions
All tests - Pearson Correlation coefficients, Poisson regression, and Generalized Linear Model (p<0.05) confirmed the hypothesis that the discharge managing with outpatient drug release has a significant effect on the final cost avoided with cancer hospitalization.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06